Early Detection of Neuroblastoma Recurrence on 18F mFBG PET

A patient with neuroblastoma was assessed to be in remission based on clinical and standard-of-care imaging assessments, including a negative I-123 mIBG scan. Patient underwent 18F mFBG PET/CT imaging on the same day as I-123 mIBG scan as part of a clinical trial (NCT: 04724369), which showed abnormal focal uptake suspicious for lesion in the skull. Patient underwent surveillance and follow-up with standard imaging. I-123 mIBG SPECT/CT at 3 months showed no abnormalities in the skull, but repeat examination at 6 months showed positive uptake corresponding to 18F mFBG. Recurrent neuroblastoma was confirmed on MRI. This example indicates that 18F mFBG PET identified neuroblastoma recurrence 6 months earlier than the current standard-of-care imaging.